Results 41 to 50 of about 166,918 (340)

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group [PDF]

, 2019
Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established.
Badalamenti, G., Bianco, A., Colao, A., De Divitiis, C., Di Maio, S., Di Sarno, A., Dolce, P., Faggiano, A., Guarnotta, V., Leo, S., Mocerino, C., Modica, R., Ottaviano, M., Palmieri, G., Puliafito, I., Riccardi, F., Tafuto, S., Tozzi, L.   +17 more
core   +1 more source

The molecular basis for ethnic variation and histological subtype differences in prostate cancer. [PDF]

, 2013
Prostate cancer is a common malignancy among men in Western countries. Recently the morbidity and mortality of prostate cancer increase dramatically in several oriental countries including China.
Goldstein, Andrew S, Huang, Jiaoti, Zong, Yang   +2 more
core   +1 more source

Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors [PDF]

, 2015
Over the past few years, knowledge regarding the molecular pathology of sporadic pancreatic neuroendocrine tumors (PNETs) has increased substantially, and a number of targeted agents have been tested in clinical trials in this tumor type.
Ahn, Balogh, Bergers, Berruti, Capurso, Capurso, Carew, Castellano, Chamberlain, Chan, Chan, Chen, Clynes, Corbo, Corbo, Couvelard, De Wilde, Di Florio, Di Florio, Di Florio, Fazio, Fendrich, Gaur, Gurung, Han, Heaphy, Heaphy, Hobday, Hopfner, House, Jacinto, Jensen, Jiao, Karnik, Karnik, Komori, Kulke, Laplante, Loewith, Lovejoy, Luzi, Marinoni, Marion-Audibert, Mendel, Meric-Bernstam, Missiaglia, Mocellin, Panzuto, Papouchado, Passacantilli, Perren, Pàez-Ribes, Raymond, Sarbassov, Scoazec, Shah, Shi, Tang, Vinagre, Wang, Yang, Yao, Yuan, Zhang, Zhang   +64 more
core   +1 more source

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. [PDF]

, 2020
PurposeImmune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and ...
Baghdadi, Tareq Al, Blanke, Charles D, Chae, Young Kwang, Chen, Helen X, Fontaine, Annette, Gatalica, Zoran, Giles, Francis J, Hansel, Donna E, Hayward, Jourdain, Kasi, Anup, Korn, W Michael, Kurzrock, Razelle, Matrana, Marc, Mayerson, Edward, McLeod, Christine, Othus, Megan, Patel, Sandip P, Plets, Melissa, Ryan, Christopher W, Shah, Manisha H, Sharon, Elad, Singh, Preet Paul   +21 more
core  

A nationwide, multi‐institutional collaborative retrospective study of colorectal neuroendocrine tumors in Japan

Annals of Gastroenterological Surgery, 2021
Aim Neuroendocrine tumors (NETs) are one of the subtypes of neuroendocrine neoplasms and are defined as epithelial neoplasms with predominant neuroendocrine differentiation.
Tatsuro Yamaguchi, Keiichi Takahashi, Kazutaka Yamada, Hiroyuki Bando, Hideo Baba, Masaaki Ito, Kimihiko Funahashi, Hideki Ueno, Shin Fujita, Seiji Hasegawa, Yoshiharu Sakai, Kenichi Sugihara   +11 more
doaj   +1 more source

Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]

, 2018
Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma, Florento, Elena, Gatalica, Zoran, Palazzo, Juan, Sanati, Souzan, Swensen, Jeffrey, Vranic, Semir, Xiu, Joanne   +7 more
core   +2 more sources

Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors?

Endocrine Connections, 2016
To date, the value of fasting plasma acylated ghrelin (AG) and unacylated ghrelin (UAG) as potential novel biomarkers in patients with neuroendocrine tumors (NETs) is unknown.The aims of this study are to (i) compare fasting AG and UAG levels between ...
Roxanne C S van Adrichem, Aart Jan van der Lely, Martin Huisman, Richard A Feelders, Patric J D Delhanty, Wouter W de Herder, Piet Kramer   +6 more
doaj   +1 more source

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. [PDF]

, 2013
BACKGROUND: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are heterogeneous with respect to biological behaviour and prognosis. As angiogenesis is a renowned pathogenic hallmark as well as a therapeutic target, we aimed to investigate the ...
A Couvelard, A Giatromanolaki, A Rinke, AM Marion-Audibert, AT Dimou, B Terris, D Hanahan, D J Pinato, D O’Toole, DC Metz, DJ Pinato, DJ Pinato, E Raymond, EP Hui, F Panzuto, G Kloppel, HS Kim, I Albrecht, IM Modlin, J LeCouter, J Strosberg, J Zhang, JC Yao, JT Chi, JY Scoazec, K Hirabayashi, K Meeran, K Villaume, M Dal Monte, M Perigny, M Ruscica, MA Maynard, N Martin, N Ngo, P Kuiper, R Dina, R Katoh, R Mentlein, R Ramachandran, R Sharma, S Ezziddin, S T K Toussi, T M Tan, VD Corleto, Y Arvidsson, Y Seo, Y Takahashi, YC Patel   +47 more
core   +2 more sources

Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?

Journal for ImmunoTherapy of Cancer
Immune checkpoint inhibitors (ICIs) revolutionized the management of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers.
Davide Ciardiello, Francesca Spada, Nicola Fazio, Maria Giulia Zampino, Lorenzo Gervaso, Rivadavio Antunes Oliveira, Michele Borghesani, Lorenzo Guidi, Lavinia Benini, Laura Algeri, Chiara Alessandra Cella   +10 more
doaj   +1 more source

Intrapancreatic accessory spleen false positive to 68Ga-Dotatoc: case report and literature review [PDF]

, 2019
Background: Intrapancreatic accessory spleen (IPAS) is an uncommon finding of pancreatic mass. Differential diagnosis with pancreatic tumor, especially with non-functional neuroendocrine tumor (NF-NET), may be very hard and sometimes it entails ...
Bellato, V., Caronna, R., Cerasari, S., Chirletti, P., Ciardi, A., Cicconi, S., Feola, T., Lancellotti, F., Muttillo, E. M., Sacco, L.   +9 more
core   +1 more source